Enleofen was founded as a spin-out from NHCS, SingHealth and Duke-NUS Medical School focused on developing new anti-fibrotic therapies.
Employees: 1-10
Investors 1
| Date | Name | Website |
| - | NSG Ventur... | nsg.ventur... |
Mentions in press and media 3
| Date | Title | Description |
| 17.06.2020 | All in on IL-11, Frazier unveils latest startup with dual focus on fibrosis and cancer | In late 2017, a team of Singaporean scientists published a Nature paper highlighting what they call a “groundbreaking” and “outstanding” new target for fibrosis. Interleukin-11, a cytokine downstream of the well-known T... |
| 09.01.2020 | Singapore biotech could get more than $1B from Boehringer Ingelheim under partnership | Enleofen’s lead product candidate – in studies to enable the company to seek regulatory approval to move it into the clinic – is ENx108A an antibody that targets IL-11 and has been shown preclinically to reverse organ dysfunction by targeti... |
| - | Singapore biotech could get more than $1B from Boehringer Ingelheim under partnership | One of Germany’s largest drugmakers is partnering with a Southeast Asian company to develop drugs for fibrotic diseases. Boehringer Ingelheim, a privately owned company based in Ingelheim am Rhein, Germany, said Thursday that it had partner... |